ME 344

Drug Profile

ME 344

Alternative Names: ME-344; NV-344

Latest Information Update: 14 Sep 2016

Price : $50

At a glance

  • Originator Novogen
  • Developer MEI Pharma; Sarah Cannon Research Institute; Spanish National Cancer Research Centre; Tennessee Oncology
  • Class Antineoplastics; Isoflavones; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cervical cancer; Ovarian cancer; Small cell lung cancer
  • Phase I Solid tumours
  • Phase 0 Breast cancer

Most Recent Events

  • 01 Aug 2016 Phase-0 for Breast cancer (First-line therapy, Combination therapy) in Spain (IV) (NCT02806817; 9202665)
  • 01 Jul 2016 MEI Pharma terminates a phase I/II trial in Ovarian cancer (Combination therapy, Late-stage disease), Cervical cancer (Combination therapy, Late-stage disease) and Small cell lung cancer (Combination therapy, Late-stage disease) in USA and United Kingdom due to lack of efficacy (NCT02100007)
  • 02 Sep 2015 Mei Pharma has patent protection for ME 344 in USA and Europe (Mei Pharma, Form 10-K, September 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top